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	Abstract 
Aims: Untreated opioid use disorder (OUD) is associated with overdose, premature death 
and infectious disease, including human immunodeficiency virus (HIV) and Hepatitis C 
(HCV). While prior studies have shown that educational interventions are associated with 
improvements in HIV and HCV knowledge and reductions in risk behaviors, those 
examined to date have typically been time- and resource-intensive.  We recently 
developed an HIV+HCV Education intervention which aims to improve HIV and HCV 
knowledge in a single visit using an automated iPad platform.  In this project, we 
examined its ability, using a within-subject evaluation, to improve knowledge of HIV and 
HCV transmission and risks among adults with OUD.  
Methods: Participants were 25 adults with OUD who were enrolled in a 12-week 
randomized trial evaluating the efficacy of an Interim Buprenorphine Treatment (IBT) for 
reducing illicit opioid use while awaiting entry into community-based opioid treatment.  
Participants completed a baseline HIV+HCV knowledge assessment (Pre-Test) followed 
by corrective feedback, both administered via iPad.  They then completed an interactive 
HIV flipbook and animated HCV video, also on iPad, followed by a second 
administration of the knowledge assessment (Post-Test).  Finally, to evaluate whether any 
changes in knowledge persisted over time, the HIV+HCV assessment was administered 
again at 4 and 12 weeks following study intake.   
Results:  At baseline (Pre-Test), participants answered 69% and 65% of items correctly 
on the HIV and HCV assessments, respectively.  After completing the educational 
intervention, participants answered 86% of items correctly on both the HIV and HCV 
assessments (p’s<.001).  These improvements in knowledge also persisted throughout the 
three-month study, with scores at Week 4 and 12 timepoints significantly greater than 
baseline (p’s<.001).  
Conclusion: An HIV+Hepatitis Education intervention delivered via a portable, 
automated iPad platform may produce significant and persistent improvements in HIV 
and HCV knowledge among adults with OUD.  These data provide additional support for 
the use of mobile educational interventions for enhancing HIV and HCV knowledge in 
individuals at elevated risk for infectious disease.  
Support: This trial was supported by NIDA R34 DA3730385 (Sigmon) with additional 
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Comprehensive Literature Review 
 
Rates of opioid abuse, including heroin and prescription opioids, have reached 
epidemic proportions in the United States (US), resulting in infectious disease, overdoses, 
premature deaths and vast economic costs (Birnbaum et al., 2011; Clausen, Waal, 
Thoresen, & Gossop, 2009; Rudd, Aleshire, Zibbell, & Gladden, 2016).  Of particular 
concern is the disproportionate prevalence of human immunodeficiency virus (HIV) and 
Hepatitis C (HCV) among individuals with opioid use disorder (OUD).  Untreated OUD 
is associated with unprecedented recent outbreaks of HIV and HCV (Dunn et al., 2016; 
Wang, Zhang, & Ho, 2011).  In 2014 alone, for example, HIV accounted for over 13,000 
deaths and HCV-related deaths reached a record high of nearly 20,000 (CDC, 2015, 
2016).  
Improving HIV and HCV knowledge  
 Risk of contracting and transmitting infectious disease among individuals with 
OUD and other substance abuse disorders primarily stems from engaging in risky drug 
use behaviors (e.g., sharing injection equipment like syringes, cookers, and cottons, 
impaired decision making under drug influence) as well as risky sexual behaviors (e.g., 
trading sex for drugs, having sex without a condom, having unprotected sex with other 
drug users).  Efforts to enhance HIV and HCV knowledge and decrease risk behaviors in 
this vulnerable population are critical for reducing the individual and societal 
consequences associated with infectious disease.   
 Educational interventions are a widely-used approach for addressing this issue, 
and interventions to date have generally focused on improving HIV and HCV knowledge 
(Arain et al., 2016), decreasing self-reported risk behaviors (Copenhaver, Johnson, Lee, 
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Harman, & Carey, 2006; Meader, Li, Jarlais, & Pilling, 2010), and improving utilization 
of HIV and HCV screening and treatment (Lubega, Agbim, Surjadi, Mahoney, & Khalili, 
2013; Marinho et al., 2016).  Overall, educational interventions have been generally 
associated with increased knowledge, self-reported condom use and entry into screening 
and treatment services, as well as decreased injection and non-injection drug use and 
trading of sex for drugs (Coffin, Rowe, & Milo Santos, 2015; Copenhaver, Johnson, Lee, 
Harman, Carey, et al., 2006; MacArthur et al., 2014; Meader, Li, Des Jarlais, & Pilling, 
2010; Shah & Abu-Amara, 2013).  Similar findings have been reported for educational 
interventions focused on HCV.  In a recent review of 10 HCV educational interventions, 
for example, 80% of the studies showed significant improvements in HCV-related 
knowledge (Shah & Abu-Amara, 2013).  Decreases in self-reported engagement in HCV 
risk behaviors and drug use, as well as increased condom use, were also demonstrated 
(Coffin et al., 2015).  Taken together, the extant data suggest that HIV and HCV 
educational interventions are associated with improvements in related knowledge, 
reductions in risk behaviors, and increased utilization of screening and treatment services 
(Marinho et al., 2016; Munoz-Plaza et al., 2008; Norton et al., 2014; Zeremski et al., 
2014).  Despite this, however, several features of these interventions have limited their 
widespread use.  First, they are often time- and resource-intensive, typically delivered 
across multiple lengthy sessions, despite some evidence that brief interventions can 
produce outcomes that are similar to longer-duration interventions (Meader et al., 2010).  
They have also traditionally relied on trained peer, staff, or health care professionals for 
intervention delivery (e.g., nurse, physician, therapist) (Shah & Abu-Amara, 2013).  
Overall, this labor-intensive approach can increase cost and time burdens.  Finally, staff-
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delivered assessments and interventions may be less appealing to some individuals due to 
potential concerns regarding confidentiality or perceived judgment around the sensitive 
illicit drug use and sexual behaviors being assessed.   
Prior studies by our group 
 Our research group previously developed a single-visit intervention for improving 
HIV and HCV knowledge in illicit drug abusers.  Briefly, the participant first completes 
an initial, paper-and-pencil assessment of baseline HIV and HCV knowledge (Pre-Test).  
She or he then views an educational video and meets individually with a master’s level 
therapist to review and discuss the video as well as an informational pamphlet.  The 
therapist then reviews the participant’s answers on the Pre-Test, provides corrective 
feedback for any incorrect answers, and answers any questions the participant has about 
the content reviewed.  Finally, the participant completes the HIV and HCV knowledge 
assessment a second time (Post-Test).   
 Across three studies with cocaine- or opioid-dependent individuals, this single-
visit, educational intervention was associated with significant increases in HIV and HCV 
knowledge accuracy (Dunn et al., 2013; Heil, Sigmon, Mongeon, & Higgins, 2005; 
Herrmann et al., 2013).  Data presented in Figure 1 offer a representative illustration of 
pre- and post-intervention outcomes in our prior study with opioid-dependent individuals, 
with participants demonstrating an approximately 55% increase in correct answers 
following the educational session (Dunn et al., 2013).  
Automating delivery of HIV+HCV assessments and education 
 Although our educational intervention was associated with improvements in HIV 
and HCV knowledge, its in-person delivery involving a master’s level therapist may still 
	 4	
limit its use in resource-constrained settings.  One exciting recent development that may 
hold promise for overcoming this limitation is the increasing use of mobile health 
(mHealth) platforms.  mHealth interventions use portable computerized devices and can 
extend the reach of health care by permitting delivery of monitoring, education, point-of-
care diagnostics and treatment beyond the confines of the medical office (Boyer, 
Smelson, Fletcher, Ziedonis, & Picard, 2010).  
 The potential utility of mHealth applications for improving knowledge has been 
evaluated with a variety of medical conditions, including cancer (Coughlin et al., 2016), 
chronic obstructive pulmonary disease (Sobnath et al., 2017), and alcohol abuse 
(Gustafson et al., 2014).  However, fewer studies have examined their utility in the areas 
of HIV and HCV knowledge (Catalini, Philbrick, Fraser, Mechael, & Israelski, 2013; 
Niakan, Mehraeen, Noori, & Gozali, 2017).  In one recent study, Festinger and 
colleagues (2016) evaluated the efficacy of an mHealth HIV educational intervention in 
increasing screening rates and reducing self-reported sexual and drug use risk behaviors 
in substance abusers participating in drug court in Philadelphia, PA.  Compared to an 
attention control condition, participants who received the educational intervention 
reported a significantly greater likelihood of HIV testing (p=0.03) and condom use 
(p<0.01).  Another recent study evaluated an mHealth intervention to increase HIV and 
HCV knowledge and testing among injection drug users attending a community syringe 
exchange program in Bronx, NY (Aronson, Bennett, Marsch, & Bania, 2017).  While 
improvements in HIV and HCV knowledge were modest, the intervention was associated 
with a high rate of testing, with 100% and 91% of participants agreeing to HIV and HCV 
screening, respectively.  
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 While these interventions have generally supported the potential utility of 
mHealth-delivered HIV and HCV education, the studies were conducted in urban 
geographic areas and the educational interventions were not integrated into opioid agonist 
treatment, which is the standard of care for treating OUD and an ideal platform for 
delivering HIV and HCV assessments and education.  We have been interested in 
examining whether automated interventions may offer promise for improving infectious 
disease knowledge among high-risk individuals in the rural and suburban areas struggling 
with outbreaks of infectious disease as well as limited treatment access for OUD and its 
associated consequences.  Additionally, we are interested in developing and evaluating an 
educational intervention that could be readily incorporated into a larger treatment 
program for individuals with OUD. 
Present study 
 The most widely-used and efficacious approach for treating OUD involves 
maintenance therapy with agonist medications (e.g., methadone, buprenorphine).  Opioid 
agonist treatment (OAT) has been consistently shown to reduce illicit opioid use, other 
drug use and drug-related overdose (Johnson et al., 2000; Kresina & Lubran, 2011; 
Schwartz, Gryczynski, O’Grady, et al., 2013), as well as HIV and HCV risk behaviors, 
infection and transmission (Gowing, Farrell, Bornemann, Sullivan, & Ali, 2011; Norton 
et al., 2017; Woody et al., 2014).   OAT also may provide an ideal setting for the delivery 
of HIV and HCV education, prevention and screening efforts, as well as efforts to 
connect patients with community resources for infectious disease testing and 
management (Carey, Huang, Linas, & Tsui, 2016; Norton et al., 2017; Perlman et al., 
2015).  
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 Despite the demonstrated efficacy of OAT for reducing illicit opioid use and 
infectious disease risk behaviors, opioid treatment clinics often struggle with extremely 
limited resources, particularly around staff availability and time.  There can be lengthy 
waitlists for methadone or buprenorphine treatment access, particularly in rural 
geographic areas (Sigmon, 2014), which further increases risk for infectious disease, 
morbidity, and mortality (Clausen et al., 2009; Peles, Schreiber, & Adelson, 2013).  Our 
research group has been developing and evaluating an interim buprenorphine dosing 
regimen that integrates buprenorphine with several additional technology-based 
components with the aim of reducing illicit drug use and other risk behaviors in OUD 
awaiting entry into a more comprehensive community treatment clinic (Sigmon, Ochalek, 
Meyer, et al., 2016).  One of those technology-assisted components is an HIV+HCV 
educational intervention, which we adapted from our original therapist-delivered format 
for automated delivery via an iPad platform.  The primary aim of the present project was 
to examine the effectiveness and acceptability of this novel mHealth HIV+HCV 
educational module for enhancing HIV and HCV knowledge, using a within-subjects 
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Aims: Untreated opioid use disorder (OUD) is associated with overdose, premature death 
and infectious disease, including human immunodeficiency virus (HIV) and Hepatitis C 
(HCV). While prior studies have shown that educational interventions are associated with 
improvements in HIV and HCV knowledge and reductions in risk behaviors, those 
examined to date have typically been time- and resource-intensive.  We recently 
developed an HIV+HCV Education intervention which aims to improve HIV and HCV 
knowledge in a single visit using an automated iPad platform.  In this project, we 
examined its ability, using a within-subject evaluation, to improve knowledge of HIV and 
HCV transmission and risks among adults with OUD.  
Methods: Participants were 25 adults with OUD who were enrolled in a 12-week 
randomized trial evaluating the efficacy of an Interim Buprenorphine Treatment (IBT) for 
reducing illicit opioid use while awaiting entry into community-based opioid treatment.  
Participants completed a baseline HIV+HCV knowledge assessment (Pre-Test) followed 
by corrective feedback, both administered via iPad.  They then completed an interactive 
HIV flipbook and animated HCV video, also on iPad, followed by a second 
administration of the knowledge assessment (Post-Test).  Finally, to evaluate whether any 
changes in knowledge persisted over time, the HIV+HCV assessment was administered 
again at 4 and 12 weeks following study intake.   
Results:  At baseline (Pre-Test), participants answered 69% and 65% of items correctly 
on the HIV and HCV assessments, respectively.  After completing the educational 
intervention, participants answered 86% of items correctly on both the HIV and HCV 
assessments (p’s<.001).  These improvements in knowledge also persisted through the 
three-month study, with scores at Week 4 and 12 timepoints significantly greater than 
baseline (p’s<.001).  
Conclusion: An HIV+Hepatitis Education intervention delivered via a portable, 
automated iPad platform may produce significant and persistent improvements in HIV 
and HCV knowledge among adults with OUD.  These data provide additional support for 
the use of mobile educational interventions for enhancing HIV and HCV knowledge in 
individuals at elevated risk for infectious disease.  
Support: This trial was supported by NIDA R34 DA3730385 (Sigmon) with additional 






Rates of opioid abuse, including heroin and prescription opioids, have reached 
epidemic proportions in the United States (US), resulting in infectious disease, overdoses, 
premature deaths and vast economic costs (Birnbaum et al., 2011; Clausen, Waal, 
Thoresen, & Gossop, 2009; Rudd, Aleshire, Zibbell, & Gladden, 2016).  Of particular 
concern is the disproportionate prevalence of human immunodeficiency virus (HIV) and 
Hepatitis C (HCV) among individuals with opioid use disorder (OUD).  Untreated OUD 
has been associated with unprecedented recent outbreaks of HIV and HCV (Dunn et al., 
2016; Wang, Zhang, & Ho, 2011).  In 2014 alone, for example, HIV accounted for over 
13,000 deaths and HCV-related deaths reached a record high of nearly 20,000 (CDC, 
2015, 2016).  
Risk of contracting and transmitting infectious disease among individuals with 
OUD and other substance abuse disorders primarily stems from engaging in risky drug 
use behaviors (e.g., sharing injection equipment like syringes, cookers, and cottons, 
impaired decision making under drug influence) as well as risky sexual behaviors (e.g., 
trading sex for drugs, having sex without a condom, having unprotected sex with other 
drug users).  Efforts to enhance HIV and HCV knowledge and decrease risk behaviors in 
this vulnerable population are critical for reducing the individual and societal 
consequences associated with infectious disease.   
Educational interventions are a widely-used approach for addressing this issue, 
and interventions to date have generally focused on improving HIV- and HCV-related 
knowledge (Arain et al., 2016), decreasing self-reported risk behaviors (Copenhaver, 
Johnson, Lee, Harman, & Carey, 2006; Meader, Li, Jarlais, & Pilling, 2010), and 
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improving utilization of HIV and HCV screening and treatment (Lubega, Agbim, Surjadi, 
Mahoney, & Khalili, 2013; Marinho et al., 2016).  Overall, educational interventions 
have been generally associated with increased knowledge, self-reported condom use and 
entry into screening and treatment services, as well as decreased injection and non-
injection drug use and trading of sex for drugs (Coffin, Rowe, & Milo Santos, 2015; 
Copenhaver, Johnson, Lee, Harman, Carey, et al., 2006; MacArthur et al., 2014; Meader, 
Li, Des Jarlais, & Pilling, 2010; Shah & Abu-Amara, 2013).  However, several features 
have limited their widespread use.  The interventions have often been delivered across 
multiple lengthy sessions and have also typically relied on delivery by trained peer, staff, 
or health care professionals (e.g., nurse, physician, therapist) (Shah & Abu-Amara, 2013).  
These factors can increase cost and time burdens associated with education delivery.  
Staff-delivered assessments and interventions may also be less appealing to some 
individuals due to potential concerns regarding confidentiality or perceived judgment 
around the sensitive illicit drug use and sexual behaviors being assessed.      
One recent development that may hold promise for overcoming this limitation is 
the increasing use of mobile health (mHealth) platforms.  mHealth interventions use 
portable computerized devices and can extend the reach of health care by permitting 
delivery of monitoring, education, point-of-care diagnostics and treatment beyond the 
confines of the medical office (Boyer, Smelson, Fletcher, Ziedonis, & Picard, 2010).  
Although few studies have examined the utility of mHealth approaches in the areas of 
HIV and HCV knowledge, the limited data to date suggests this approach may be 
promising for addressing infectious disease knowledge (Aronson et al., 2017; Catalini, 
Philbrick, Fraser, Mechael, & Israelski, 2013; Festinger et al., 2016; Niakan, Mehraeen, 
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Noori, & Gozali, 2017).  
We recently adapted a single-visit, therapist-delivered educational intervention, 
which was developed and shown by our group in prior studies to improve HIV and HCV 
knowledge in illicit drug abusers (Dunn et al., 2013; Heil, Sigmon, Mongeon, & Higgins, 
2005; Herrmann et al., 2013), for automated delivery using an iPad platform.  As a first 
step toward examining the potential of this novel mHealth application for improving HIV 
and HCV knowledge in individuals with OUD, we sought here to characterize its effects 
in the sample of individuals seeking but waitlisted for opioid agonist maintenance.  
2. Methods 
2.1 Parent trial  
The HIV+HCV educational intervention was examined as part of a larger trial 
evaluating a multi-component interim buprenorphine regimen individuals with OUD.  
The overarching aim of the parent, 12-week randomized clinical trial was to examine the 
initial efficacy of interim buprenorphine dosing for reducing illicit opioid use and other 
risk behaviors during waitlist delays to community treatment.  Participants were 
randomized to Interim Buprenorphine Treatment (IBT; n=25) or a continued waitlist 
control condition (WLC; n=25).  IBT participants visited the clinic bi-monthly for staff-
observed medication ingestion and urinalysis, with the remaining doses dispensed via 
computerized device at home (Med-O-Wheel Secure; Addoz, Finland).  They also 
received daily calls assessing drug use, craving and withdrawal via an Interactive Voice 
Response (IVR) phone system, as well as IVR-generated random call-backs and 
HIV+HCV Education. Waitlist control participants remained on the waitlist of their local 
clinic and did not receive these services.  All participants completed 4-, 8- and 12-week 
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assessments that included the self-report and staff-administered questionnaires and 
provision of urine specimens.  The primary outcomes from this study demonstrated the 
efficacy of IBT and have been reported previously (Sigmon, Ochalek, Meyer, et al., 
2016).  Therefore, below we briefly describe the details most relevant to this secondary 
analysis of the HIV+HCV educational component. 
2.2 Participants 
 To be eligible for the parent trial, participants had to be >18 years old, meet 
Diagnostic and Statistical Manual (DSM-5; American Psychiatric Association, 2013) 
criteria for OUD, and provide an opioid-positive urine specimen at intake.  Participants 
who were pregnant and/or nursing, had a significant psychiatric, and/or had medical 
illness that interfered with participation were excluded.  As only IBT participants 
received the HIV+HCV education intervention described below, our analyses in this 
project focused on those individuals randomized to the IBT condition. 
2.3 HIV+HCV educational intervention 
 During Study Week 1, participants completed a baseline assessment (Pre-Test) of 
HIV and HCV knowledge and perceived risk using an interactive iPad application 
developed by us (described below), after which the application provided immediate 
corrective feedback and explanation for any incorrect items.  Prior to the intervention, 
study staff gave the participant a brief (approximately 1-minute) orientation.  The 
participant then reviewed an interactive flipbook (“HIV/AIDS Basics,” Aids.gov) and 
watched a 15-minute video (“What is Hepatitis C and how is it diagnosed?,” amfAR: The 
Foundation for AIDS Research), both administered via iPad.  The HIV+HCV knowledge 
assessment was then administered again (Post-Test), with immediate feedback again 
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provided for any incorrect answers.  At the end of the session, a staff member offered 
condoms, as well as contact information for free HIV and HCV testing resources.  To 
examine the extent to which changes in HIV and HCV knowledge persisted following the 
single-visit intervention, participants repeated the Post-Test knowledge assessment at two 
subsequent timepoints (i.e., Study Weeks 4 and 12). 
2.4 Measures  
 The knowledge assessment consisted of a modified version of the Marsch 
HIV/AIDS Knowledge Test (Marsch et al., 2005), a 50-item assessment of HIV 
knowledge in three areas (i.e., general knowledge, sexual risk behaviors, drug risk 
behaviors) (Table 1).  Also included was a 17-item test assessing general knowledge of 
HCV (Dunn et al., 2013; Table 2).  Both assessments were administered via iPad and 
included “True”, “False”, or “Don’t know” response options (Herrmann et al., 2013), 
with correct responses summed to obtain an overall accuracy score (i.e., percent correct) 
for each questionnaire.   
 Participants also completed a series of visual analog scale (VAS) items evaluating 
their perceived risk of infection and disease knowledge, as well as HIV and HCV risk 
behaviors (Table 3).  On three additional VAS items, participants rated the helpfulness of 
the HIV iPad flipbook, the helpfulness of the HCV video, and their comfort with the iPad 





2.5 Data analyses 
 Descriptive statistics were used to characterize participants’ baseline 
demographics and drug use history.  The percentage of items correct on the HIV and 
HCV assessments were calculated for each participant at the Pre-Test, Post-Test, and 
Week 4 and 12 follow-up assessments, with higher scores indicating greater knowledge 
accuracy.  The significance associated with temporal changes in mean scores was 
evaluated using a linear mixed model for repeated measures data (SAS, PROC MIXED).  
Pairwise comparisons among timepoints were performed using a Fisher’s LSD 
procedure.  To identify knowledge deficits in specific content areas, McNemar’s tests 
were used to evaluate changes in accuracy on individual items.  Analyses of temporal 
changes on the VAS items paralleled those described above for knowledge scores, with 
the exception of the three VAS items assessing the perceived helpfulness of the 
intervention components (i.e., HIV+HCV iPad application, HCV video, iPad) which were 
descriptively examined at the Post-Test timepoint.  Based on our prior estimates of 
subject to subject variability and expected correlation between time points, the study was 
estimated to have power (1-β)=.80 using α=.05 to detect a mean difference of less than 
10% between any two time points for our primary outcome measures (i.e., 8.5% and 
9.6% for HIV and HCV respectively).  All statistical analyses were performed using SAS 





3.1 Participant characteristics 
 With regard to participants’ drug use characteristics at intake, 64% and 36% of 
participants reported heroin or prescription opioids as their primary opioid of abuse, 
respectively (Table 4).  Fifty-six percent endorsed the intravenous (IV) route as their 
primary route of opioid administration, while 28% and 16% reported oral/sublingual and 
intranasal routes, respectively.  Eighty percent of participants endorsed a lifetime history 
of IV drug use and 40% reported a history of opioid overdose.  Of those reporting a 
lifetime history of overdose, 89% had experienced multiple overdoses.  Twenty-eight 
percent reported past-month use of cocaine.   
 Related to participants’ infectious disease risk more specifically, among those 
with a history of IV drug use, 30% reported using a syringe or needle after someone and 
15% had used an unsterilized syringe or needle (Table 5).  Twelve percent of 
participants’ partners were also opioid users, and 67% of those partners reported IV as 
their primary route of administration.  In terms of sexually-transmitted diseases, 14% of 
participants received a chlamydia diagnosis in their lifetime and 6%, 2%, and 2% of 
participants had been previously diagnosed with gonorrhea, herpes, and viral warts, 
respectively.  While no participants reported an HIV diagnosis, 22% of participants had 




3.2 HIV knowledge 
 On the baseline (Pre-test) HIV knowledge assessment, participants answered an 
average of 69% of items correctly (Table 6).  Following delivery of the educational 
intervention, the average percent correct significantly increased to 86% (t(66)= -9.49, 
p<.001) (Figure 2, top panel).  A similar pattern was seen for the three content areas on 
General, Sexual Risk and Drug Risk knowledge (Table 6).  Examination of individual 
items showed that significant increases were seen on 13 of the 50 (26%) individual items 
(Table 6).   
 At the Week 4 and 12 follow-up timepoints, participants answered 84% and 86% 
of items on the HIV knowledge assessment correctly, respectively.  These scores were 
significantly greater than the Pre-Test baseline (p’s<.001) and did not significantly differ 
from one another.  
3.3 HCV knowledge 
 On the baseline (Pre-Test) HCV knowledge assessment, participants answered 
65% of overall items correctly (Table 7).  Following delivery of the educational 
intervention, the percent of correct items significantly increased to 86% (t(66)= -6.89, 
p<.001) (Figure 2, bottom panel).  Examination of individual items showed that 
significant increases were seen on 4 of the 17 (24%) individual items.  
 At the Week 4 and 12 follow-ups, participants answered 80% and 81% of items 
on the HCV knowledge assessment correctly, respectively.  These scores were 
significantly greater than baseline (p’s<.001) and did not differ from one another.  
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3.4 Visual analog scale items 
 Significant Pre- to Post-Test increases were also observed in participants’ 
perceived knowledge of HIV and HCV transmission on the VAS items (range: 0-100), 
including “How much do you know about how HIV is transmitted?” (54 vs. 82, 
respectively; t(60)= -6.65, p<.001) and “How much do you know about how HCV is 
transmitted?” (55 vs. 82, respectively; t(60)= -5.73, p<.001).  Ratings on these items at 
Study Weeks 4 and 12 remained significantly greater than Pre-Test (p’s<.001).  Finally, 
with regard to intervention acceptability more generally, participants’ mean ratings on the 
perceived helpfulness of the intervention components (range: 0-100) were 79, 81 and 89 
for HIV+HCV iPad application, Hepatitis C video and iPad, respectively. 
4. Discussion 
 Given the current US opioid public health crisis, there is a critical need to address 
and reduce infectious disease transmission among individuals with OUD.  This sample of 
waitlisted, opioid-dependent adults presented with considerable risk for contraction or 
transmission of HIV and HCV.  For example, 80% of participants reported a history of 
IV drug use, 56% identified the IV route as their primary route of opioid use, and 30% 
had previously shared a needle or syringe.  Additionally, 56% of participants reported a 
history of unprotected sex and 12% had a current partner that also used opioids.     
 With regard to HIV-related knowledge, participants demonstrated baseline levels 
of accuracy (69% of items correct) that was generally consistent with prior studies 
(Copenhaver et al., 2006; Dunn et al., 2013; Heil et al., 2005; Herrmann et al., 2013).  
	 18	
Similar baseline levels were seen on HCV knowledge (65% correct items), which is also 
consistent with previous studies (Arain et al., 2016; Marinho et al., 2016; Norton et al., 
2014; Shah & Abu-Amara, 2013; Zeremski et al., 2016).  However, the HCV baseline 
knowledge scores observed here were higher than those in our prior study among 
individuals with OUD (Dunn et al., 2013) (65% vs. 47%, respectively).  The greater 
baseline knowledge seen in the present study may be a function of general increases in 
knowledge among individuals with OUD in the several years since our previous study.  
Also worth noting is that this study sample reported a greater lifetime history of IV drug 
use (80% vs. 43%, respectively) and prior opioid treatment (68% vs. 39%, respectively) 
than the Dunn et al. (2013) sample.  Other studies have reported greater HCV knowledge 
in injection vs. noninjection drug users, perhaps because injection drug users may interact 
more extensively with treatment or syringe exchange providers and thus encounter some 
educational content from these programs (Marinho et al., 2016; Strauss et al., 2007).  
 Our automated HIV+HCV educational intervention was associated with 
significant improvements in both HIV and HCV knowledge, with 25% and 32% 
increases in overall score accuracy from Pre- to Post-Test, respectively.  The magnitude 
of HIV knowledge gains is similar to our group’s previous interventions with both 
cocaine- and opioid-dependent adults (Dunn et al., 2013; Heil et al., 2005; Herrmann et 
al., 2013).  Our findings on the degree of HCV knowledge improvements are consistent 
with (Arain et al., 2016) or higher than (Marinho et al., 2016; Norton et al., 2014; 
Zeremski et al., 2016) recent studies on this topic by other research groups.  In contrast, 
the increases in HCV knowledge scores were smaller than those seen in our earlier trial 
with opioid-dependent adults (Dunn et al., 2013) (32% vs. 78%, respectively), likely due 
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to the higher HCV baseline knowledge scores seen here than in that earlier study.  
 Improvements in HIV+HCV knowledge persisted over the 12 weeks following 
the educational intervention.  To our knowledge this is the first demonstration of 
sustained effects of a single-visit, mHealth educational intervention on infectious disease 
knowledge.  The mechanism underlying this persistence in knowledge improvements is 
unclear.  For example, how long the effect would remain beyond the 12-week timepoint 
is an empirical question and could be addressed more definitively in future studies.  
Overall more direct examination of the duration of improvements in HIV and HCV 
knowledge following brief mHealth interventions is warranted.  
 Finally, participants rated the educational content and iPad platform favorably, 
which is also consistent with prior studies evaluating mHealth platforms for HIV and 
HCV education among individuals with OUD (Niakan et al., 2017; Shrestha et al., 2017; 
Westergaard et al., 2017).  These findings provide additional support for the use of 
technology-assisted educational interventions among individuals seeking treatment for 
OUD (Miller & Himelhoch, 2013; Shrestha et al., 2017).   
 Several strengths of this study are worth noting.  This is the first educational 
intervention, to our knowledge, to target HIV and HCV knowledge among the high-risk 
sample of waitlisted individuals with OUD and the first to demonstrate sustained 
improvements for several months following the intervention.  The study also has several 
limitations.  First, this was a within-subject evaluation conducted within the context of a 
larger randomized trial that did not include an HIV+HCV education control group.  
However, our group has previously demonstrated that the improvements in HIV and 
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HCV knowledge are not likely due to a practice effect from repeated exposure to the 
knowledge assessments (Herrmann et al., 2013).  Second, we did not include measures of 
sexual and drug-use risk behaviors and thus were unable to directly examine the extent to 
which this educational intervention influenced frequency of HIV+HCV-related risk 
behaviors.  However, prior studies have reported a strong concordance between HIV and 
HCV education and reductions in high-risk behaviors, as well as increases in protective 
health behaviors (Copenhaver et al., 2006; Gilchrist et al., 2017; Meader et al., 2010; 
Shah & Abu-Amara, 2013).  Finally, this study did not include HIV or HCV screening 
and thus we cannot evaluate whether infectious disease status changed as a function of 
the educational intervention.   
 In summary, an automated mHealth educational intervention was associated with 
significant and sustained improvements in knowledge of HIV+HCV transmission and 
risk behaviors in this extremely vulnerable group of individuals with OUD.  This 
mHealth iPad intervention can be implemented with relatively modest financial, time and 
staff burdens, which may facilitate its use in settings in which resources are limited.  
Given the continuing opioid epidemic, efforts are urgently needed to reduce HIV and 
HCV contraction and transmission among individuals with OUD.  Mobile health 
educational interventions may offer a time- and cost-effective approach for addressing 




HIV Knowledge Questionnaire  
1. HIV causes AIDS.     
2. Once you have HIV, you have it for life.   
3. Cleaning needles with water will kill HIV.  
4. AIDS is a disease of gay, white men.   
5. HIV can be transmitted from one person to another during vaginal sexual intercourse.  
6. People who are HIV positive always look sick.   
7. Injection drug users are also at risk of Hepatitis C infection; 50-90 % of HIV infected  
    injection drug users are also infected with Hepatitis C.       
8. HIV can be transmitted from one person to another through anal sex, but not through 
    oral sex.  
9. A person can become infected with HIV by sharing needles with other drug users.  
10. A person cannot get AIDS from a toilet seat.   
11. Condoms reduce the risk of transmission of the HIV virus. 
12. HIV can be transmitted from one person to another by sharing “drug works”, such as 
     “cookers” or “cottons”. 
13. A person cannot get AIDS from pre-ejaculatory fluids.  
14. Transferring a drug from one syringe to another can transmit HIV.  
15. AIDS is not always fatal.     
16. An infected mother can give HIV to her infant via breast feeding (milk). 
17. Intranasal or injection drug users are the fastest growing risk group for HIV. 
18. Rubbing injection sites with alcohol can lower the risk of getting AIDS. 
19. AIDS is a preventable disease. 
20. Women on birth control pills cannot get HIV during sexual intercourse. 
21. Putting a needle in a flame before using it will prevent infection from the HIV virus.  
22. Using bleach to clean drug works after each use greatly reduce the risk of getting 
      AIDS  
23. The HIV virus can be transmitted if blood from an infected person gains entry into  
      another person. 
24. The HIV virus is present in vaginal secretions.  
25. The HIV virus can be transmitted by hugging or holding hands. 
26. There is currently no known cure for AIDS. 
27. Needles bought on the street in a sterile wrapper cannot transmit HIV.    
28. It is safe to re-use bleach after someone else has used it to clean their  “drug works”.  
29. Wiping of a needle before using it is an effective HIV risk-reducing strategy. 
30. HIV can be transmitted from an infected mother to her child before or during  
      childbirth.  
31. Latex condoms are better than natural skin or lambskin condoms in preventing the  
      spread of HIV. 
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32. HIV can be transmitted through menstrual blood. 
33. Vaseline can be safely used to lubricate a condom.  
34. The HIV virus can be transmitted by mosquitoes or bugs. 
35. It is safe to re-use a condom as long as the male did not ejaculate in the condom.  
36. A person who has had a sexually transmitted disease is at increased risk for HIV.  
37. A person can be infected by HIV by giving blood at a blood bank. 
38. If a person is infected with HIV, he or she will feel sick within a few days to a week   
      after infection. 
39.  HIV can not be transmitted if an infected needle penetrates the skin only, because the 
       needle must enter the blood stream in order for infection to occur.   
40. AIDS can be transmitted when an infected person coughs or sneezes on another  
      person.  
41. Condoms that are not long enough to cover the whole penis may not be able to  
       prevent the transmission of HIV.     
42. Using oil-based lubricants, such as hand lotion, cold cream, food products or baby oil, 
      with a condom will weaken the condom and increase the likelihood that may break   
      during sex.  
43. Boiling “drug works” for 15 minutes before each use will reduce the likelihood of  
      becoming infected with the AIDS virus.  
44. People with AIDS can be cured if they are given very good medical care. 
45. A person who becomes infected with HIV may not test positive for the virus for up to  
      4 weeks to 6 months after infection. 
46. Drug users can increase their chances of getting AIDS by sharing water, in which     
      needles or syringes are dipped, with another user. 
47. HIV can be transmitted from IV drug users to their sexual partners.  
48. HIV can be transmitted during a blood transfusion if HIV-contaminated blood is  
      used.    
49. People with AIDS can get severe illnesses, which are not usually a threat to people 
      without AIDS.   









HCV Knowledge Questionnaire 
1. Hepatitis is a virus that causes inflammation of the liver.   
2. It is possible to transmit hepatitis C to other people before you begin to experience    
    any symptoms of the virus.   
3. There is a vaccine available for Hepatitis C.  
4. The risk of transmission of infection through unprotected sex is lower for Hepatitis C   
     than HIV.  
5. There is only one test that can be used to diagnose the Hepatitis C infection. 
6. You can be treated for Hepatitis C, but it is very hard to permanently cure.  
7. People who contract Hepatitis C usually feel sick within 1-2 days of contracting the    
    virus.   
8. Hepatitis C is spread easily through sexual contact. 
9. You can die from Hepatitis C.   
10. It is dangerous to continue drinking alcohol after learning that you have contracted 
      Hepatitis C.   
11. Hepatitis C is primarily transmitted blood to blood. 
12. There are 6 different types of Hepatitis C; the main difference between them is that 
       some are easier to cure than others.     
13. Hepatitis C is spread by forms of social contact, such as kissing, hugging, and 
      touching.   
14. Symptoms of Hepatitis may include fatigue and abdominal pain.  
15. Most individuals with Hepatitis C exhibit no recognizable signs or symptoms. 
16. Hepatitis C can be cured in 100 percent of people who begin treatment. 
17. 30 out of 100 people with chronic Hepatitis C infection may not actually   
      develop liver problems, but can still transmit the infection through blood-to 










Table 3.  
VAS items 
1. How high of a chance do you think of having HIV? 
2. How high of a chance do you think you have of getting Hepatitis C? 
3. How much do you know about how HIV is transmitted? 
4. How much do you know about how Hepatitis C is transmitted? 
5. What is the likelihood that you will use a condom next time you have sex? 
6. If you were going to have sex and no condom was available, what is the chance that  
    you would refrain from having unprotected sex? 
7. Do you ever use a needle to inject drugs? 
8. What is the likelihood that you will use a new, sterile syringe, cooker, and cotton next  
     time you inject? 
9. If you were going to ‘shoot up’ and only a used needle was available, what is the   
    chance that you would be able to refrain from using the needle? 
10. How helpful was the Hepatitis C video?  
11. How helpful was this HIV+HCV iPad application? 




Table 4.  
Participant baseline characteristicsa (n=25)  
Age, yrs 33.6 ± 10.0 
Male, % 60 
Employed full-time, % 48 
Education, yrs 12.4 ± 2.4 
Primary past year opioid of abuse, %  
   Heroin 64 
   Prescription opioids 36 
Primary route of opioid administration, %  
   Oral/sublingual 28 
   Intranasal 16 
   Inhalation 0 
   Intravenous 56 
Duration of regular opioid use, yrs 6.4 ± 5.8 
Ever used IV, % 80 
Past-month cocaine use, % 28 
Duration on treatment waitlist, mos 3.3 ± 2.5 
Buprenorphine dose, mg 13.2 ± 1.1 










Table 5.  
HIV+HCV Risk Behaviors at Intake (n=25)  
Ever used IV, % 80 
Age first IV use, (Mean±SD) 26±8.5 
Ever used syringe/needle after someone, % 30 
Ever used unsterilized syringe/needle, % 15 
Partner uses opioids, % 12 
Partner’s primary route of administration, %  
   Intravenous 67 
   Oral/sublingual 33 
Ever received diagnosis, %  
   Chlamydia 14 
   Gonorrhea 6 
   Herpes 2 
   Viral warts 2 






















Significant HIV Pre- to Post-Test Improvements 
Item Pre-Test %  Post-Test %  P-value 
Total Score 69% 86% <.001 
General Knowledge 72% 88% <.001 
15. AIDS is not always fatal. (F) 28% 56% 0.039 
16. An infected mother can give HIV to her infant  
      via breast feeding (milk). (T) 
32% 88% <.001 
32. HIV can be transmitted through menstrual  
      blood. (T) 
52% 96% 0.001 
34. The HIV virus can be transmitted by   
      mosquitoes or bugs. (F) 
32% 72% 0.002 
44. People with AIDS can be cured if they are    
      given very good medical care. (F) 
60% 92% 0.022 
Sexual Risk Knowledge 63% 89% <.001 
24. The HIV virus is present in vaginal secretions.      
      (T)  
32% 80% <.001 
31. Latex condoms are better than natural skin or  
      lambskin condoms in preventing the spread of  
      HIV. (T) 
44% 88% 0.003 
36. A person who has had a sexually transmitted  
      disease is at increased risk for HIV. (T) 
24% 76% <.001 
41. Condoms that are not long enough to cover the  
      whole penis may not be able to prevent the  
      transmission of HIV. (T) 
52% 84% 0.022 
42. Using oil-based lubricants, such as hand lotion,  
      cold cream, food products or baby oil, with a  
      condom will weaken the condom and increase 
      the likelihood that it may break during sex. (T) 
44% 96% <.001 
Drug Risk Knowledge 70% 83% <.001 
18. Rubbing injection sites with alcohol can lower  
      the risk of getting AIDS. (T) 
20% 80% <.001 
27. Needles bought on the street in a sterile   
      wrapper cannot transmit HIV. (F) 
44% 76% 0.022 
43. Boiling “drug works” for 15 minutes before  
     each use will reduce the likelihood of becoming  
     infected with the AIDS virus. (T) 
24% 68% 0.003 
Only items in which changes in accuracy from Pre- to Post-Test were significant (p<.05) 





Significant HCV Pre- to Post-Test Improvements 
Item Pre-Test %  Post-Test %  P-value 
3. There is a vaccine available for Hepatitis C.  
(F) 
32% 64% 0.022 
5. There is only one test that can be used to     
diagnose the Hepatitis C infection. (F) 
8% 80% <.001 
12. There are 6 different types of Hepatitis C; 
   the main difference between them is that 
   some are easier to cure than others. (T) 
44% 84% 0.021 
16. Hepatitis C can be cured in 100 percent of  
       people who begin treatment. (F) 
44% 92% <.001 
Only items in which changes in accuracy from Pre- to Post-Test were significant (p<.05) 
are presented; correct answers are denoted in parentheses (T=True, F=False) 
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Figure Legend 
Figure 1. Mean percent of correct items on the HIV and HCV Knowledge questionnaires 
in a prior study of an in-person HIV+HCV educational intervention with opioid-
dependent adults (Dunn et al., 2013). Asterisks denote significant differences (p<.01) 
between scores on knowledge assessments administered Pre-Test (black bar) and Post-
Test (grey bar).  
Figure 2. Mean percent of correct items on the HIV and HCV knowledge assessments in 
the present study.  Data bars sharing a common letter are not significantly different 
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